Explore the Therapeutic Composition and Mechanism of Schisandra chinensis-Acorus tatarinowii Schott on Alzheimer’s Disease by Using an Integrated Approach on Chemical Profile, Network Pharmacology, and UPLC-QTOF/MS-Based Metabolomics Analysis
Table 3
Identification and change trends of biomarkers.
HMDB
Measured mass
Formula
Mass error (ppm)
Compounds
Pathway
Change fold
SG/MG
MG/BG
HMDB0002177
305.2482
C20H32O2
2.14
cis-8,11,14,17-Eicosatetraenoic acid
Linoleic acid metabolism
↑
↓
HMDB0006323
359.2949
C24H38O2
1.36
Tetracosapentaenoic acid (24:5n-3)
Linoleic acid metabolism
—
↑
HMDB0001381
375.2138
C20H32O5
-1.1
Prostaglandin H2
Arachidonic acid metabolism
↑
↓
HMDB0000277
379.2491
C18H38NO5P
0.99
Sphingosine 1-phosphate
Sphingolipid metabolism
↓
↑
HMDB0000252
300.2891
C18H37NO2
-1.94
Sphingosine
Sphingolipid metabolism
↓
—
HMDB0012225
164.0481
C9H8O3
4.77
Enol-phenylpyruvate
Phenylalanine metabolism
↓
↑
HMDB0002302
207.1131
C11H11NO2
1.35
Indole-3-propionic acid
Phenylalanine metabolism
↓
↑
HMDB0001903
417.3379
C27H44O3
3.74
Calcitriol
Vitamin B6 metabolism
—
↓
HMDB0004702
297.2436
C18H32O3
4.1
12,13-EpOME
Oxylipin metabolism
—
↓
HMDB0001434
212.0927
C10H13NO4
4.59
3-Methoxytyrosine
L-dopa degradation
↓
↑
HMDB0000913
230.1031
C10H12O5
3.64
Vanillactic acid
L-dopa degradation
↓
↓
HMDB0002057
1079.401
C40H70N7O18P3S
-3.42
Pristanoyl-CoA
Fatty acid metabolism
↓
↑
HMDB0002177
305.2482
C20H32O2
2.14
cis-8,11,14,17-Eicosatetraenoic acid
Linoleic acid metabolism
↑
↓
Notes: , per group; data are expressed as . The up (↑) and down (↓) arrows represent the relative increasing or decreasing trend of the metabolites;“—” represents no significant differences between SG and MG; a change trend of MG vs. NG, for a -test, and (SG: Sc-At group; MG: model group; BG: blank group).
